Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

Fig. 3

Progression-free survival in patients with EGFR wild-type and EGFR mutated tumors assessed per RECIST v1.1 by investigator and overall survival. a Progression-free survival in cohorts 1 to 4 by cohort. b Progression-free survival in cohorts 1 to 4 by histology and overall. c Progression-free survival in cohort 5. d Overall survival in cohorts 1 to 4 by cohort. e Overall survival in cohorts 1 to 4 by histology and overall. f Overall survival in cohort 5

Back to article page